Andrew Koutnik
Andrew Koutnik is a researcher in the fields of nutrition, exercise physiology, and metabolism. His published research focuses on the effects of carbohydrate intake, exogenous ketone supplementation, and ketogenic diets on exercise performance, metabolism, and cognitive function. Additionally, his work investigates the physiological and cardiovascular impacts of nutritional interventions in individuals with type 1 diabetes.
42 claims checked on air: 5 context 1 contradicted 2 overstated 25 supported 9 unverified
What they said on air - supported
4 citing their own research
Fat oxidation rates in keto-adapted athletes exceeded previously reported medical literature, with some athletes oxidizing over 1.85 grams of fat per minute during physical activity.
"fat metabolism made up the majority of fuel substrate during this activity at a level of fat oxidation that was higher than any fat levels ever reported in the medical literature. Some athletes were over 1.85 g of fat burned per minute during physical activity." (said at 0:00:15)
In the FASTER study (Volek et al., 2016), investigators evaluated 20 elite ultra-endurance runners adhering to either a traditional high-carbohydrate diet or a long-term low-carbohydrate ketogenic diet. Keto-adapted athletes achieved mean peak fat oxidation rates of 1.54 ± 0.18 g/min (with individual peak values exceeding 1.8 g/min), compared to 0.67 ± 0.14 g/min in high-carbohydrate runners. Fat oxidation accounted for an average of 88% of total energy expenditure during submaximal exercise, representing the highest fat oxidation rates documented in exercise physiology literature. The evidence is rated low certainty due to the cross-sectional design and small sample size (n=20).
Starting a ketogenic diet lowers blood glucose and insulin levels, causing an immediate loss of water weight followed by an automatic reduction in caloric intake.
"when people get on to a ketogenic diet, they almost immediately—they're lowering their glucose, which causes a lowering of insulin, and essentially that causes a cascade of events, which you drop water weight, so you essentially lose weight almost instantly. Then, by default, the evidence shows that people volitionally reduce their caloric intake" (said at 0:13:29)
The speaker accurately describes established physiological responses to ketogenic diets. Restricting carbohydrate intake lowers circulating glucose and insulin levels, prompting rapid depletion of glycogen stores and excretion of bound water (along with natriuresis), resulting in immediate early weight loss. Furthermore, systematic reviews and controlled ad libitum feeding trials demonstrate that ketogenic states suppress appetite and hunger, leading individuals to spontaneously reduce their caloric intake.
- supports: Atkins and other low-carbohydrate diets: hoax or an effective tool for weight loss? (Lancet (London, England) ) · cited 426x in the literature
"The apparent paradox that ad-libitum intake of high-fat foods produces weight loss might be due to severe restriction of carbohydrate depleting glycogen stores, leading to excretion of bound water, the ketogenic nature of the diet being appetite suppressing, the high protein-content being highly satiating and reducing spontaneous food intake, or limited food choices leading to decreased energy intake." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Effects of a high-protein ketogenic diet on hunger, appetite, and weight loss in obese men… (The American journal of clinical nutrition 2008) · cited 443x in the literature
"Ad libitum energy intakes were lower with the LC diet than with the MC diet [P=0.02; SE of the difference (SED): 0.27] at 7.25 and 7.95 MJ/d, respectively. Over the 4-wk period, hunger was significantly lower (P=0.014; SED: 1.76) and weight loss was significantly greater (P=0.006; SED: 0.62) with the LC diet (6.34 kg) than with the MC diet (4.35 kg)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Do ketogenic diets really suppress appetite? A systematic review and meta-analysis. (Obesity reviews : an official journal of the International Association for the Study of Obesity 2015) · cited 368x in the literature
"individuals adhering to KLCD were less hungry and had a reduced desire to eat. Although these absolute changes in appetite were small, they occurred within the context of energy restriction, which is known to increase appetite in obese people. Thus, the clinical benefit of a ketogenic diet is in preventing an increase in appetite, despite weight loss, although individuals may indeed feel slightly less hungry (or more full or satisfied)." (abstract, results, passage verified)
pubmedfull study (doi)
Patients with type 1 diabetes have a life expectancy reduced by 10 to 20 years and have a tenfold higher risk of cardiovascular disease.
"you're supposed to live 10 to 20 years shorter, you're supposed to get at least one chronic complication of typically retinopathy of the eyes, neuropathy of the nerves, nephropathy of the kidneys, or you have tenfold higher risk of cardiovascular disease." (said at 0:16:20)
Large nationwide registry studies confirm that individuals with type 1 diabetes face a substantial reduction in life expectancy and elevated risk of microvascular and macrovascular complications. A population-based study in Scotland found that at age 20, individuals with type 1 diabetes experienced an estimated loss of life expectancy of 11.1 years for men and 12.9 years for women compared to the general population, with ischemic heart disease and microvascular end-stage organ damage driving much of the excess mortality. Cardiovascular disease risk is markedly elevated in type 1 diabetes compared to matched controls, particularly in early-onset disease.
In 1796, physician John Rollo reversed type 2 diabetes in two patients by lowering carbohydrates.
"in 1796, John Rollo was a physician who applied these tools in type 2 diabetes to reverse two patients with type 2 diabetes condition with lowering carbohydrates." (said at 0:23:38)
Historical medical literature documents that in late 1796, British military physician John Rollo successfully treated diabetes mellitus in two patients (most notably Captain Meredith) by placing them on an animal-based diet that strictly restricted carbohydrates and vegetable matter, leading to the resolution of glycosuria and symptoms. While modern distinctions between type 1 and type 2 diabetes did not exist in the 18th century, medical historians recognize these patients as having what is now classified as non-insulin-dependent (type 2) diabetes. Because this historical evidence consists of an uncontrolled two-patient case series, the certainty of evidence is very low.
In the 1860s, William Banting resolved his obesity by self-administering a lower-carbohydrate dietary approach.
"We know that in 1860s that there was William Banting who actually went on to self-administer a lower carbohydrate approach and was able to resolve all of his own obesity." (said at 0:23:55)
The historical record confirms that in the 1860s, William Banting effectively resolved his obesity by following a dietary regimen that restricted carbohydrates (specifically sugars and farinaceous/starchy foods) under the guidance of Dr. William Harvey, which Banting documented in his widely published 1863 pamphlet 'Letter on Corpulence, Addressed to the Public'. Modern medical and nutritional literature widely acknowledges Banting's 1863 case as the first popular low-carbohydrate diet for obesity management.
The ketogenic diet has been utilized clinically for over a century to reduce the frequency and severity of epileptic seizures.
"We've known for over 100 years that it's been applied to reduce the frequency and severity of seizures and epilepsy." (said at 0:24:38)
The claim is accurate. Dr. Russell Wilder at the Mayo Clinic first proposed and clinically introduced the ketogenic diet to treat epilepsy in 1921—over 100 years ago—to mimic the anti-seizure effects of fasting. Clinical studies throughout the 1920s documented its application in hundreds of patients, and contemporary systematic reviews confirm that ketogenic diets effectively reduce seizure frequency in individuals with drug-resistant epilepsy.
Diabetic ketoacidosis is characterized by high glucose levels, deficient or near complete absence of insulin, and unregulated ketone levels that can exceed 10 millimolar.
"When someone's in diabetic ketoacidosis, there is high glucose levels, deficient or near complete absence of insulin, and unregulated ketone levels, sometimes north of 10 millimolar per liter." (said at 0:32:40)
Diabetic ketoacidosis (DKA) is characterized by severe relative or absolute insulin deficiency, marked hyperglycemia (conventionally defined as blood glucose >250 mg/dL), and excessive, uncontrolled hepatic ketogenesis leading to severe ketosis and metabolic acidosis. Clinical evaluations and diagnostic thresholds establish that circulating ketone concentrations (notably beta-hydroxybutyrate and acetoacetate) are markedly elevated in DKA, frequently reaching and exceeding levels around 8 to 10 mmol/L or higher.
In nutritional ketosis, glucose and insulin are maintained at regulated levels with ketones typically ranging from 0.3 to around 5 millimolar.
"in nutritional ketosis, in the context of diabetes or not, it is normal and regulated glucose levels, low but still present insulin. So, it's not an absence of insulin like in DKA, it's just a lower level of insulin that keeps glucose and ketones in regulated levels. And ketone levels range anywhere, I would actually change that barometer from 0.3 millimoles per liter upwards of a rough estimate around 5 millimolar." (said at 0:33:15)
The speaker's definition of nutritional ketosis matches established clinical and metabolic definitions. In nutritional ketosis, basal insulin levels remain low but sufficient to prevent the runaway lipolysis and severe metabolic derailment seen in diabetic ketoacidosis (DKA). Consequently, blood glucose remains regulated via gluconeogenesis, while blood beta-hydroxybutyrate (BOHB) levels rise from baseline (~0.1 mM) into a physiological, therapeutic range typically spanning from ~0.3–0.5 mM up to approximately 3.0–5.0 mM.
Individuals on high-carbohydrate diets almost never have blood beta-hydroxybutyrate levels above 0.3 millimolar.
"when you look at studies where people are on higher carbohydrate approaches, there's almost a complete they're almost never above 0.3 millimolar." (said at 0:37:31)
Published nutritional and metabolic studies demonstrate that individuals consuming standard or high-carbohydrate diets maintain baseline and postprandial blood beta-hydroxybutyrate (βHB) concentrations well below 0.3 mmol/L (typically ranging from <0.05 to 0.2 mmol/L). On high-carbohydrate diets, elevated postprandial insulin suppresses lipolysis and hepatic ketogenesis, preventing βHB from reaching threshold levels of nutritional ketosis (often defined as ≥0.5 mmol/L) or exceeding 0.3 mmol/L in the absence of extended fasting or prolonged strenuous exercise.
- supports: Relationship between Ketones, Ghrelin, and, Appetite on Isocaloric Diets with Varying Carb… (The Journal of nutrition 2023) · cited 8x in the literature
"Although βHB increased significantly more with the LCHF diet than with the acellular diet after 3 m (mean: 0.16 mmol/L; 95% CI: 0.09, 0.24), this did not correspond to a significant group difference in ghrelin (unless the 2 high-carbohydrate groups were combined [mean: -39.6 pg/mL; 95% CI: -76, -3.3])." (abstract, results, passage verified)
pubmedfull study (doi) - supports: The effects of initiating a 24-hour fast with a low versus a high carbohydrate shake on gl… (Nutrition & metabolism 2025) · cited 2x in the literature
"Nutritional ketosis (BHB ≥ 0.5 mmol/L) was reached on average by 12 h in the LC/HF condition but was not reached at any point during the fast on average in the HC/LF condition." (abstract, results, passage verified)
pubmedfull study (doi)
The brain metabolizes beta-hydroxybutyrate for energy in a dose-dependent manner based on circulating levels.
"we've known that since the 1960s that it can actually be utilized for brain energy metabolism. And it's utilized in for the by the brain in a dose-dependent manner, meaning the more that's present, the more your body is going to metabolize." (said at 0:40:05)
Human metabolic and kinetic studies confirm that cerebral uptake and subsequent oxidation (metabolism) of beta-hydroxybutyrate are directly and linearly related to circulating arterial ketone concentrations.
Beta-hydroxybutyrate directly blocks the NLRP3 inflammasome.
"There's also an anti-inflammatory properties where it has been shown to directly even block certain what they call inflammasomes. Inflammasomes, they know NLRP3 inflammasome is a great example." (said at 0:41:20)
Preclinical and in vitro research demonstrates that the ketone body β-hydroxybutyrate (BHB) specifically suppresses activation of the NLRP3 inflammasome. Mechanistic work in human monocytes and mouse models showed that BHB prevents potassium efflux and ASC oligomerization, blocking downstream caspase-1 activation and the production of pro-inflammatory cytokines IL-1β and IL-18, independently of its oxidation or GPR109A receptor signaling.
1,3-butanediol-based exogenous ketones elevate blood hydrogen ions, increase blood oxygen saturation (SpO2), and improve cognitive function in acute hypoxia.
"One of the effects of 1,3-butanediol based products... is that you have a slight change in the hydrogen ion levels within the blood. And that subtle elevation hydrogen ions in the blood seems to change the ability to uptake oxygen levels within through ventilation... and even in those extreme settings, we were seeing that you we increase SPO2, increase resilience against cognitive decline, and actually improve cognitive function against uh uh a placebo-controlled arm." (said at 0:43:00)
The speaker's description matches findings from randomized, placebo-controlled crossover trials evaluating (R)-3-hydroxybutyl (R)-3-hydroxybutyrate (a 1,3-butanediol-based ketone monoester) under acute hypoxic conditions. In a randomized crossover trial of 16 military personnel exposed to acute severe hypoxia (simulating 6,096 m / 9.7% O2) at rest, ingestion of the ketone monoester attenuated the decline in blood oxygen saturation (SpO2 was 76.8% vs. 70.4% in placebo, P = 0.049) and attenuated cognitive performance decline during the Defense Automated Neurobehavioral Assessment code substitution task (+6.8 correct responses/min compared to placebo, P = 0.018). While a companion study during exercise in hypoxia found that ketone monoesters attenuated SpO2 desaturation without a statistically significant cognitive benefit, the specific resting severe hypoxia trial demonstrates the SpO2 and cognitive improvements described.
- context: Ketone monoester attenuates oxygen desaturation during weighted ruck exercise under acute … (Experimental physiology 2024) · cited 10x in the literature
"The decline in oxygen saturation during hypoxic exposure was attenuated in KME conditions by 2.4%-4.2% (P < 0.05) compared with placebo. Outcomes of cognitive performance tasks, in the form of the Defense Automated Neurobehavioral Assessment (DANA) code substitution task, the Stroop color and word task, and a shooting simulation, did not differ between trials before and during hypoxic exposure." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Ketone monoester attenuates declines in cognitive performance and oxygen saturation during… (Experimental physiology 2024) · cited 16x in the literature
"Declines in cognitive performance during hypoxic exposure, assessed as cognitive efficiency during a Defense Automated Neurobehavioral Assessment (DANA) code substitution task, were attenuated with KME leading to 6.8 (95% CL: 1.0, 12.6) more correct responses per minute compared to PLA (P = 0.018). The decline in S p O 2 during hypoxic exposure was attenuated (6.40% S p O 2 ; 95% CL: 0.04, 12.75; P = 0.049) in KME compared to PLA (KME, 76.8 ± 6.4% S p O 2 ; PLA, 70.4 ± 7.4% S p O 2 ). Acute ingestion of KME attenuated the decline in cognitive performance during acute severe hypoxic exposure, which coincided with attenuation of declines in O 2 saturation." (abstract, results, passage verified)
pubmedfull study (doi)
Medium-chain triglycerides were first clinically evaluated in the 1950s and 1960s as a therapeutic dietary intervention to promote weight gain in malnourished children.
"what's interesting about MCTs is they were the first quote-unquote exogenous ketone that had actually been studied for therapeutic use back in the 1950s and 60s for malnutrition disorders in children. So, kids that were undernourished or not able to grow sufficiently, they were actually given MCTs. The theory was that this was a way of overcoming some of the malnutrition issues that some of these children had in the gut. And it effectively worked. It increased body weight in these children" (said at 0:48:45)
Medium-chain triglycerides (MCTs) were introduced and evaluated clinically starting in the late 1950s and 1960s specifically for pediatric and adult patients suffering from gastrointestinal malabsorption syndromes, impaired lipid digestion, and associated malnutrition or failure to thrive. Because MCTs undergo rapid hydrolysis, do not strictly require bile salts or pancreatic micelle formation, and are transported directly via the portal vein rather than the lymphatic system, their administration successfully provided absorbable caloric energy and promoted weight gain in undernourished children with intestinal and lymphatic disorders.
Diets supplemented with medium-chain triglycerides (MCTs) work almost as effectively as standard ketogenic diets in managing epilepsy.
"there have been studies actually showing that MCT-based diets or uh natural forms of fat that convert to ketone bodies in epilepsy have also been shown to work almost as effectively as just ketogenic diets do uh in and of themselves." (said at 0:48:50)
Randomized controlled trial evidence demonstrates that medium-chain triglyceride (MCT) ketogenic diets have comparable efficacy to classical ketogenic diets for seizure control in intractable pediatric epilepsy. In a randomized clinical trial of 145 children (Neal et al., 2009), there were no statistically significant differences in seizure reduction or the proportion of patients achieving >50% or >90% seizure reduction between the classical and MCT-based diets at 3, 6, and 12 months. Systematic reviews and network meta-analyses also confirm similar overall efficacy across these dietary therapy variations.
- supports: A randomized trial of classical and medium-chain triglyceride ketogenic diets in the treat… (Epilepsia 2009) · cited 439x in the literature
"After 3, 6, and 12 months there were no statistically significant differences in mean percentage of baseline seizures between the two groups (3 months: classical 66.5%, MCT 68.9%; 6 months: classical 48.5%, MCT 67.6%; 12 months: classical 40.8%, MCT 53.2%; all p > 0.05). There were no significant differences between groups in numbers achieving greater than 50% or 90% seizure reduction." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Impact of medium-chain triglyceride with and without ketogenic diet in the management of d… (Nutritional neuroscience 2026)
"One paediatric RCT found no clear difference in seizure outcomes between MCT KD and the classical ketogenic diet (CKD), despite higher ketone levels with CKD; however, equivalence was not established." (abstract, results, passage verified)
pubmedfull study (doi)
Studies by Louise Burke and John Hawley found a 2% performance decline in elite race walkers on a low-carbohydrate diet lasting 5 days to 3 weeks.
"in 2017 to 2021, prominent researchers who do really, really rigorous research studied low carbohydrate intake—Louise Burke, John Hawley, and a few others—where they lowered carbohydrates in elite race walkers for 5 days to 3 weeks... And what they found is that while the athletes were transitioning into ketosis, they were already producing ketone bodies, but not fully transitioned by all measures, at least not confirmed, they saw a deterioration in performance, but only 2%." (said at 0:55:45)
A landmark 2017 study led by Louise Burke and John Hawley (part of the Supernova research series) investigated the effects of a 3-week ketogenic low-carbohydrate, high-fat (LCHF; <50 g/day carbohydrate) diet during intensified training in elite race walkers. The authors found that while high-carbohydrate groups improved their 10 km race walk times by 5.3% to 6.6%, the LCHF group experienced a 1.6% (approximately 2%) decline in performance (-1.6% [90% CI: -8.5%, 5.3%]) alongside impaired exercise economy (increased oxygen cost of movement).
Research by George Cahill in the 1960s showed that normalization of key brain energy metabolites during fasting or very low carbohydrate intake takes around 3 weeks.
"We have known since the 1960s, David, from George Cahill, that when individuals go on to these very low carbohydrate approaches, and the most extreme rapid form of that is a fast, that even we don't see a normalization of key brain energy metabolites until around after 3 weeks in duration." (said at 0:57:15)
Seminal metabolic research led by George Cahill and Oliver Owen in 1967 demonstrated that during prolonged starvation (several weeks), the human brain undergoes a major metabolic shift wherein ketone bodies (beta-hydroxybutyrate and acetoacetate) replace glucose as the primary fuel source. While this adaptation occurs progressively over several weeks of fasting to stabilize cerebral energy requirements, the original experimental catheterization data relied on a very small sample (3 obese patients undergoing 5 to 6 weeks of starvation).
Athletes keto-adapted for over 4 weeks performing at above 85% VO2 max derived the majority of fuel from fat, with fat oxidation rates exceeding 1.85 grams per minute.
"when we looked at what was fueling these athletes up to over 85% of their VO2 max, fat metabolism made up the majority of fuel substrate during this activity, and at a level of fat oxidation that was higher than any fat levels ever reported in the medical literature. Some athletes were over 1.85 grams of fat burned per minute during physical activity." (said at 0:59:15)
The statement describes findings from the FASTER (Fat Adapted Substrate oxidation in Trained Elite Runners) study by Volek and colleagues (PMID: 26892521). In this cross-sectional comparison of 20 elite ultra-endurance athletes, runners keto-adapted for an average of 20 months (range 9–36 months) exhibited a mean peak fat oxidation rate of 1.54 ± 0.18 g/min (compared to 0.67 ± 0.14 g/min in high-carbohydrate runners), with individual maximal fat oxidation rates in keto-adapted athletes reaching or exceeding 1.85 g/min. In these athletes, fat remained the predominant fuel source up to approximately 85% of VO2max, substantially shifting the metabolic crossover point seen in traditional high-carbohydrate athletes. The certainty of evidence is low due to the small cross-sectional observational design (n=20).
Ironman competitors on a 6-week ketogenic diet sustained 70% VO2 max cycling performance without deterioration compared to a high-carb diet despite experiencing higher rates of hypoglycemia.
"what we wanted them to do was sustain 70% of their VO2 max on a cycle bike for as long as they could before they fatigued below the 70% threshold... What we were finding is that when we compared the same athlete for 6 weeks on both of these diets... we found that yet again, athletes on the ketogenic diet did not see a deterioration in performance. But what was absolutely critical to this, David, is that the athletes on the ketogenic diet actually had a higher incidence of hypoglycemia. Yet, they maintained the equivalent level of physical performance." (said at 1:01:30)
A randomized crossover study in trained triathletes compared 6 weeks of a very-low-carbohydrate/ketogenic diet (40 g/day) versus a high-carbohydrate diet (380 g/day) during strenuous cycling time-to-exhaustion tests at 70% VO2 max. The trial found that time-to-exhaustion performance was maintained without deterioration on the ketogenic diet compared to the high-carbohydrate diet, while the low-carbohydrate condition resulted in lower glucose levels / exercise-induced hypoglycemia unless minimal carbohydrate supplementation was provided.
Administering 10 grams of carbohydrates per hour during prolonged strenuous exercise improved endurance performance by 22% in both high-carbohydrate and ketogenic athletes.
"Well, when we gave 10 g per hour on both the high-carb diet and the low-carbohydrate ketogenic diet, both diets improved performance 22%." (said at 1:06:11)
A randomized crossover study in trained triathletes adapted to either a 6-week high-carbohydrate (380 g/day) or a very-low-carbohydrate/ketogenic (40 g/day) diet tested endurance capacity during a cycling time-to-exhaustion test at 70% VO2max. Administering a low dose of carbohydrates (10 g/h) during exercise prevented exercise-induced hypoglycemia and increased time to exhaustion by exactly 22% across both the high-carbohydrate and ketogenic diet conditions.
An average-weight male can store roughly 500 grams of carbohydrates (up to 2,000 kcal) as muscle glycogen, whereas females store approximately 300 grams.
"The average body weight male can probably hold somewhere between 500 g of carbohydrates, that's up to 2,000 calories in the form of muscle glycogen, females around 300 or so, obviously a little bit more than that if you're well trained." (said at 1:10:13)
Human metabolic balance and physiological studies show that skeletal muscle glycogen stores in average-sized, healthy adult males typically hold around 400 to 500 grams of carbohydrates (yielding roughly 1,600 to 2,000 kcal, calculated at 4 kcal/g), while females store proportionately less (around 300 to 400 grams) due primarily to differences in average body mass and skeletal muscle mass. Classical overfeeding and glycogen-loading studies demonstrate that glycogen storage capacity is approximately 15 g/kg of body weight and can accommodate an expansion of ~500 g.
There are medical case reports of individuals weighing over 400 pounds who fasted for over a year.
"There's examples of individuals north of 400 lb that have fasted for over a year." (said at 1:10:47)
A well-documented medical case report published in 1973 describes a 27-year-old male weighing 456 lb (207 kg) who underwent medically supervised therapeutic starvation for 382 days (over a year), consuming only water, non-caloric fluids, vitamin, and mineral supplements. As a single case report, the evidence design is uncontrolled and rated as very low certainty regarding the safety or generalizability of prolonged therapeutic starvation.
Adipose tissue is highly sensitive to insulin, such that subtle amounts of insulin dramatically blunt fat breakdown and lipolysis.
"The fat binds insulin at very high potency, meaning you need very little amounts of insulin at the fat to actually shut down fat metabolism. Not completely, but largely, okay? You dramatically blunt fat breakdown with just subtle amounts of insulin." (said at 1:11:34)
The claim is supported by established clinical and physiological evidence. Adipose tissue is exceptionally sensitive to the antilipolytic action of insulin. Classic hyperinsulinemic-euglycemic clamp and microdialysis studies in humans show that the half-maximal inhibitory concentration (EC50/IC50) of insulin required to suppress lipolysis and free fatty acid release is very low (roughly 10–15 μU/mL or ~50–70 pmol/L), which is near or slightly above basal fasting levels. Consequently, subtle physiological increments in circulating insulin dramatically blunt lipolysis and fat breakdown long before reaching the concentrations required to stimulate maximal peripheral glucose disposal.
- supports: Suppression of systemic, intramuscular, and subcutaneous adipose tissue lipolysis by insul… (The Journal of clinical endocrinology and metabolism 2000) · cited 62x in the literature
"The insulin concentrations resulting in a half-maximal suppression (EC50) of systemic lipolysis, adipose tissue, and muscle lipolysis were 51, 68, and 44 pmol/L, respectively (between one another, P < 0.001)." (abstract, results, passage verified)
pubmedfull study (doi) - supports: Optimizing measures of insulin-regulated lipolysis in humans. (American journal of physiology. Endocrinology and metabolism 2025) · cited 1x in the literature
"For 40 of 46 studies, calculating FFA palmitate IC 50 using data from both steps of a EHC overestimated FFA palmitate IC 50 compared with the first (low) dose, which suppressed palmitate Ra by > 50%." (abstract, results, passage verified)
pubmedfull study (doi)
Studies published in JAMA in 1924 and 1925 by Gordon and Levine showed that low blood glucose caused glycopenia and early onset fatigue in Boston Marathon runners.
"despite us knowing since the 1920s that low blood glucose levels from Harvard physicians in JAMA 1924, 1925, Gordon and Levine, you can look this up in JAMA, have shown that low blood glucose caused glycopenia and early onset fatigue." (said at 1:14:03)
The speaker accurately describes landmark historical research conducted on Boston Marathon runners by Harvard physicians Burgess Gordon, Samuel A. Levine, and colleagues, published in JAMA in 1924 and 1925. In the 1924 study (JAMA 82:1778–1779), post-race blood samples from runners demonstrated that profound exhaustion and collapse correlated with severe hypoglycemia (low blood glucose). In their follow-up 1925 study (JAMA 85:508–509), supplying runners with carbohydrates before and during the race prevented hypoglycemia, markedly reduced physical exhaustion, and improved finish conditions. This classic work established the role of blood glucose maintenance and carbohydrate availability in preventing fatigue during prolonged endurance exercise, a concept substantiated across a century of exercise metabolism research.
An analysis of 34 countries led by Duke researchers showed that 90% of the obesity epidemic can be explained by diet alone rather than lack of physical activity.
"In fact, a major analysis from 34 different countries from Duke and other investigative researchers all over the world including China actually showed that 90% of the obesity epidemic could be explained by diet alone and the remaining wasn't necessarily a lack of physical activity, but just alterations across individuals in energy expenditure." (said at 1:17:32)
A 2025 global analysis led by Duke University researchers (using the IAEA Doubly Labelled Water database) analyzed 4,213 adults across 34 populations worldwide. The study found that variations in body size-adjusted total energy expenditure accounted for only approximately one-tenth (~10%) of the increase in body fat percentage and BMI associated with economic development. In contrast, higher energy intake (particularly ultra-processed food consumption) accounted for the remaining ~90%, demonstrating that excess caloric intake rather than reduced physical activity is the primary driver of development-related obesity. The GRADE certainty is rated low due to the observational and cross-sectional nature of the data.
Nine out of ten American adults (90%) have suboptimal metabolic health as defined by elevated fasting blood glucose, high triglycerides, elevated waist circumference, or related biomarkers.
"nine out of 10 individuals have sub-optimal metabolic health as defined by a fasting blood glucose level that's elevated high triglycerides, elevated waistline, or some other metabolic biomarker that 9 out of 10 Americans are clearly showing adverse metabolic changes in those biomarkers." (said at 1:18:25)
A nationally representative cross-sectional study of US adults in the National Health and Nutrition Examination Survey (NHANES 2009–2016, n = 8,721) evaluated metabolic health across five key cardiometabolic biomarkers: waist circumference, fasting blood glucose/HbA1c, blood pressure, triglycerides, and HDL cholesterol, in the absence of related medications. Only 12.2% of US adults met the criteria for optimal metabolic health, meaning approximately 87.8% (nearly 9 out of 10) had suboptimal metabolic health across one or more of these parameters.
Fact-checked episodes
Publications
- Carbohydrate Ingestion on Exercise Metabolism and Physical Performance.Endocrine reviews 2026 · CEBM Level 5
- The Effects of 31-Day Exogenous Ketone Consumption on Running Performance, Cognitive Function, Metabolism, Body Composition, Hemodynamics, and Mood in Recreational Runners: A Randomized-Control Trial.Journal of the American Nutrition Association 2026 · CEBM Level 2
- Effect of Acute Ingestion of a Ketone Monoester on Psychomotor Vigilance During Acute Severe Hypoxia Exposure.Military medicine 2026 · CEBM Level 2
- Carbohydrate ingestion eliminates hypoglycemia and improves endurance exercise performance in triathletes adapted to very low- and high-carbohydrate isocaloric diets.American journal of physiology. Cell physiology 2025 · CEBM Level 2
- Multisystem impact of altering acid load of ingested exogenous ketone supplements at rest in young healthy adults.American journal of physiology. Regulatory, integrative and comparative physiology 2025 · CEBM Level 2
- Substrate Oxidation Does Not Influence Middle Distance Running Performance: A Randomized Controlled Crossover Trial.Nutrients 2025 · CEBM Level 2
- Coronary artery calcification in type 1 diabetes after 10-year ketogenic diet.Journal of applied physiology (Bethesda, Md. : 1985) 2025 · CEBM Level 4
- A comprehensive SARS-CoV-2 and COVID-19 review, Part 2: host extracellular to systemic effects of SARS-CoV-2 infection.European journal of human genetics : EJHG 2024 · CEBM Level 5
- A Ketone Monoester with Carbohydrate Improves Cognitive Measures Postexercise, but Not Performance in Trained Females.Medicine and science in sports and exercise 2024 · CEBM Level 2
- Expert consensus on nutrition and lower-carbohydrate diets: An evidence- and equity-based approach to dietary guidance.Frontiers in nutrition 2024 · CEBM Level 5
- Advanced cardiovascular physiology in an individual with type 1 diabetes after 10-year ketogenic diet.American journal of physiology. Cell physiology 2024 · CEBM Level 4
- The Metabolic and Endocrine Effects of a 12-Week Allulose-Rich Diet.Nutrients 2024 · CEBM Level 5
- Efficacy and Safety of Long-term Ketogenic Diet Therapy in a Patient With Type 1 Diabetes.JCEM case reports 2024 · CEBM Level 4
- Differential Rates of Glycation Following Exposure to Unique Monosaccharides.International journal of molecular sciences 2024 · CEBM Level 5
- Ketone monoester attenuates oxygen desaturation during weighted ruck exercise under acute hypoxic exposure but does not impact cognitive performance.Experimental physiology 2024 · CEBM Level 2
- Ketone monoester attenuates declines in cognitive performance and oxygen saturation during acute severe hypoxic exposure under resting conditions.Experimental physiology 2024 · CEBM Level 2
- Low and high carbohydrate isocaloric diets on performance, fat oxidation, glucose and cardiometabolic health in middle age males.Frontiers in nutrition 2023 · CEBM Level 2
- Metabolic and ruck performance effects of a novel, light-weight, energy-dense ketogenic bar.Experimental physiology 2023 · CEBM Level 2
- A Glutamate Scavenging Protocol Combined with Deanna Protocol in SOD1-G93A Mouse Model of ALS.Nutrients 2023 · CEBM Level 5
- Exogenous Ketone Supplements in Athletic Contexts: Past, Present, and Future.Sports medicine (Auckland, N.Z.) 2022 · CEBM Level 5
- Resting-state heart rate variability after stressful events as a measure of stress tolerance among elite performers.Frontiers in physiology 2022 · CEBM Level 4
- From bedside to battlefield: intersection of ketone body mechanisms in geroscience with military resilience.GeroScience 2021 · CEBM Level 5
- Carbohydrate restriction for diabetes: rediscovering centuries-old wisdom.The Journal of clinical investigation 2021 · CEBM Level 5
- Ketone Bodies Impact on Hypoxic CO 2 Retention Protocol During Exercise.Frontiers in physiology 2021 · CEBM Level 2
- Ketone Bodies Attenuate Wasting in Models of Atrophy.Journal of cachexia, sarcopenia and muscle 2020 · CEBM Level 5
- Effects of an Exogenous Ketone Supplement on Five-Kilometer Running Performance.Journal of human kinetics 2020 · CEBM Level 2
- Exogenous Dietary Ketone Ester Decreases Body Weight and Adiposity in Mice Housed at Thermoneutrality.Obesity (Silver Spring, Md.) 2020 · CEBM Level 5
- Nutritional Ketosis with Ketogenic Diets or Exogenous Ketones: Features, Convergence, and Divergence.Current sports medicine reports 2020 · CEBM Level 5
- Exogenous Ketone Supplements Improved Motor Performance in Preclinical Rodent Models.Nutrients 2020 · CEBM Level 5
- Investigating Ketone Bodies as Immunometabolic Countermeasures against Respiratory Viral Infections.Med (New York, N.Y.) 2020 · CEBM Level 5
- Dose response of a novel exogenous ketone supplement on physiological, perceptual and performance parameters.Nutrition & metabolism 2020 · CEBM Level 2
- Human Adaptations to Multiday Saturation on NASA NEEMO.Frontiers in physiology 2020 · CEBM Level 4
- Targeting the Warburg effect for cancer treatment: Ketogenic diets for management of glioma.Seminars in cancer biology 2019 · CEBM Level 5
- Delaying latency to hyperbaric oxygen-induced CNS oxygen toxicity seizures by combinations of exogenous ketone supplements.Physiological reports 2019 · CEBM Level 5
- Anticatabolic Effects of Ketone Bodies in Skeletal Muscle.Trends in endocrinology and metabolism: TEM 2019 · CEBM Level 5
- Concentration-Dependent Effects of a Dietary Ketone Ester on Components of Energy Balance in Mice.Frontiers in nutrition 2019 · CEBM Level 5
- Exogenous Ketones Lower Blood Glucose Level in Rested and Exercised Rodent Models.Nutrients 2019 · CEBM Level 5
- Commentary: Ketone Diester Ingestion Impairs Time-Trial Performance in Professional Cyclists.Frontiers in physiology 2018 · CEBM Level 5
- Stair climbing exercise as a novel health intervention for menopause: cardiovascular and skeletal muscle implications.Menopause (New York, N.Y.) 2018 · CEBM Level 5
- Nutritional ketosis delays the onset of isoflurane induced anesthesia.BMC anesthesiology 2018 · CEBM Level 5
- Corrigendum: Exogenous Ketone Supplements Reduce Anxiety-Related Behavior in Sprague-Dawley and Wistar Albino Glaxo/Rijswijk Rats.Frontiers in molecular neuroscience 2017 · CEBM Level 5
- Pathogenesis of depression- and anxiety-like behavior in an animal model of hypertrophic cardiomyopathy.FASEB journal : official publication of the Federation of American Societies for Experimental Biology 2017 · CEBM Level 5
- Complex I inhibition augments dichloroacetate cytotoxicity through enhancing oxidative stress in VM-M3 glioblastoma cells.PloS one 2017 · CEBM Level 5
- Exogenous Ketone Supplements Reduce Anxiety-Related Behavior in Sprague-Dawley and Wistar Albino Glaxo/Rijswijk Rats.Frontiers in molecular neuroscience 2016 · CEBM Level 5
- Impact of negative affectivity and trait forgiveness on aortic blood pressure and coronary circulation.Psychophysiology 2015 · CEBM Level 4
- Acute passive vibration reduces arterial stiffness and aortic wave reflection in stroke survivors.European journal of applied physiology 2014 · CEBM Level 2
- School burnout and cardiovascular functioning in young adult males: a hemodynamic perspective.Stress (Amsterdam, Netherlands) 2014 · CEBM Level 4
- Impact of acute whole-body cold exposure with concurrent isometric handgrip exercise on aortic pressure waveform characteristics.European journal of applied physiology 2014 · CEBM Level 2
- Long term ablation of protein kinase A (PKA)-mediated cardiac troponin I phosphorylation leads to excitation-contraction uncoupling and diastolic dysfunction in a knock-in mouse model of hypertrophic cardiomyopathy.The Journal of biological chemistry 2014 · CEBM Level 5
- Depressive symptoms contribute to increased wave reflection during cold pressor test in young adult men.American journal of hypertension 2013 · CEBM Level 4
- The effects of short term L-citrulline supplementation on wave reflection responses to cold exposure with concurrent isometric exercise.American journal of hypertension 2013 · CEBM Level 2
- Sympathetic vasomotor tone is associated with depressive symptoms in young females: a potential link between depression and cardiovascular disease.American journal of hypertension 2013 · CEBM Level 4